Taken all together, although TLR2 activation by Pam2 lipopeptides is able to induce inflammatory cytokines and activate NK cells in vitro[25], the systemic injection of Pam2 lipopeptides as cancer adjuvants is ineffective at abolishing immune suppression. Here, TLR2 is linked to cancer.